BID | 50.00 | ASK | 51.83 | ||
Open | 52.23 | Previous Close | 52.72 | ||
Pre-Market | - | After-Market | 50.56 | ||
- - | 0.46 0.92% |
Target Price | 70.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 39.72 | Finscreener Ranking | ★★★★★ 68.24 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★★ 71.72 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 84.76 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 4.27 | Earnings Rating | Strong Sell | |
Market Cap | 1.52B | Earnings Date | 4th Aug 2022 | |
Alpha | 0.05 | Standard Deviation | 0.25 | |
Beta | 1.51 |
Today's Price Range 50.0153.93 | 52W Range 47.34112.00 | 5 Year PE Ratio Range -670.0021.40 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -12.13% | ||
1 Month | -10.45% | ||
3 Months | 4.09% | ||
6 Months | -26.16% | ||
1 Year | -51.97% | ||
3 Years | 366.14% | ||
5 Years | 834.75% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 53.33 | |||
ROE last 12 Months | 44.66 | |||
ROA (5Y Avg) | 11.42 | |||
ROA last 12 Months | 38.24 | |||
ROC (5Y Avg) | 11.07 | |||
ROC last 12 Months | 42.90 | |||
Return on invested Capital Q | 12.28 | |||
Return on invested Capital Y | 9.34 | |||
Assets Turnover | 0.80 | |||
Receivables Turnover | 4.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.90 | ||||
1.36 | ||||
2.17 | ||||
3.70 | ||||
5.10 | ||||
15.88 | ||||
1.45 | ||||
43.07 | ||||
1.21B | ||||
Forward PE | -139.20 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.30 | ||||
5.40 | ||||
0.01 | ||||
0.02 | ||||
18.07K | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
77.00 | ||||
64.10 | ||||
65.50 | ||||
18.50 | ||||
47.63 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
799.81M | ||||
26.37 | ||||
257.33 | ||||
134.94 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | 0.59 | 0.59 | 0.00 |
Q01 2022 | 4.32 | 4.93 | 14.12 |
Q04 2021 | 2.66 | 3.34 | 25.56 |
Q03 2021 | 1.30 | 3.93 | 202.31 |
Q02 2021 | 2.54 | 2.47 | -2.76 |
Q01 2021 | 5.95 | 6.51 | 9.41 |
Q04 2020 | 4.36 | 6.12 | 40.37 |
Q03 2020 | 0.39 | 1.95 | 400.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.59 | -43.27 | Negative |
9/2022 QR | 0.18 | -79.55 | Negative |
12/2022 FY | 5.71 | -21.78 | Negative |
12/2023 FY | -0.43 | -115.87 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 0.59 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 601.28K |
Shares Outstanding | 30.27K |
Shares Float | 18.00M |
Trades Count | 13.04K |
Dollar Volume | 31.44M |
Avg. Volume | 338.60K |
Avg. Weekly Volume | 406.20K |
Avg. Monthly Volume | 281.29K |
Avg. Quarterly Volume | 328.31K |
Fulgent Genetics Inc. (NASDAQ: FLGT) stock closed at 52.72 per share at the end of the most recent trading day (a -11.93% change compared to the prior day closing price) with a volume of 701.31K shares and market capitalization of 1.52B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 139 people. Fulgent Genetics Inc. CEO is Ming Hsieh.
The one-year performance of Fulgent Genetics Inc. stock is -51.97%, while year-to-date (YTD) performance is -47.59%. FLGT stock has a five-year performance of 834.75%. Its 52-week range is between 47.34 and 112, which gives FLGT stock a 52-week price range ratio of 4.27%
Fulgent Genetics Inc. currently has a PE ratio of 3.90, a price-to-book (PB) ratio of 1.36, a price-to-sale (PS) ratio of 2.17, a price to cashflow ratio of 3.70, a PEG ratio of 2.32, a ROA of 38.24%, a ROC of 42.90% and a ROE of 44.66%. The company’s profit margin is 47.63%, its EBITDA margin is 65.50%, and its revenue ttm is $799.81 Million , which makes it $26.37 revenue per share.
Of the last four earnings reports from Fulgent Genetics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.59 for the next earnings report. Fulgent Genetics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Fulgent Genetics Inc. is Strong Buy (1), with a target price of $70, which is +39.72% compared to the current price. The earnings rating for Fulgent Genetics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fulgent Genetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fulgent Genetics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.83, ATR14 : 2.93, CCI20 : -183.27, Chaikin Money Flow : -0.05, MACD : 0.76, Money Flow Index : 52.56, ROC : -12.57, RSI : 30.80, STOCH (14,3) : 0.88, STOCH RSI : 0.00, UO : 40.82, Williams %R : -99.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fulgent Genetics Inc. in the last 12-months were: Han Lin Gao (Sold 950 shares of value $76 919 ), Jian Xie (Sold 32 508 shares of value $2 152 264 ), John C. Bolger (Option Excercise at a value of $13 519), John C. Bolger (Sold 1 750 shares of value $111 799 ), Paul Kim (Sold 17 401 shares of value $1 568 454 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.
CEO: Ming Hsieh
Telephone: +1 626 350-0537
Address: 4978 Santa Anita Avenue, Temple City 91780, CA, US
Number of employees: 139
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.